Skip to main content
. 2020 Jan 19;17(11):1550–1559. doi: 10.1080/15476286.2020.1712895

Figure 3.

Figure 3.

A potential application of eRNA-targeting therapeutics in cancer intervention.

Diagram showing i) antisense oligo-based drug or RNAi therapeutics that can inhibit eRNAs from activating/regulating target genes; ii) small molecule compound (denoted by the dark-red pentagon object) can be developed to inhibit eRNA–protein interaction. The pink object depicts an eRNA binding protein that is involved in the oncogenic roles of the eRNA and this enhancer.